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Summary
This chapter outlines some developments in the applications of vibrational spectroscopy for disease diagnostics and demonstrates how the applications of the
spectroscopic techniques can be extended to the analysis and evaluation of disease
aetiology and the mechanisms of interaction with and the cellular and subcellular
responses to, for example, chemotherapeutic agents and nanoparticles. The primary emphasis is on Raman spectroscopy, although some examples are based on infrared absorption spectroscopy. The studies presented are chosen to illustrate how
a range of multivariate analytical techniques can be employed to maximize the potential benefits of the complex spectral information obtained from tissue or cells.
Introduction
Vibrational Spectroscopy is a subset of spectroscopy which analyses vibrations
within a molecule (or material). The vibrations are characteristic of the molecular
structure and, in polyatomic molecules, give rise to a spectroscopic “fingerprint”.
The spectrum of vibrational energies can thus be employed to characterise a molecular structure, or changes to it due to the local environment or external factors
(eg radiation, chemical agents). Vibrational energies fall within the mid Infrared
(IR) region of the electromagnetic spectrum and are commonly probed through IR
absorption spectroscopy. Following the discovery of IR radiation by Herschel in
1800 [1], initial applications of Infrared absorption spectroscopy were limited to
astronomy and astrophysics [2]. In material sciences, significant advances were
made by 1900 when Abney and Festing recorded spectra for 52 compounds, correlating absorption bands with molecular structures [3]. Coblentz helped establish
IR spectroscopy as a routine analytical tool, cataloguing the spectra of hundreds of
substances, both organic and inorganic [3]. Technological developments post
world war II aided considerably in establishing IR spectroscopy as a routine laboratory characterisation technique, but none more so than the development of commercial Fourier Transform IR (FTIR) spectrometers in the 1960s and 70s [4,5] and
FTIR microscopes in the late 1980s [6].
IR spectroscopy is now a routine technique for materials characterisation and
has found numerous applications in forensics [7], environmental science [8] and
pharmacology [9]. Raman spectroscopy is a complementary technique with origin
in the discovery of the Raman effect in 1928 [10], for which C.V. Raman was
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awarded the Nobel prize in physics in 1930. In 1998 the Raman Effect was designated an ACS National Historic Chemical Landmark, in recognition of its importance in materials and process analysis. Raman spectroscopy remained largely
a curiosity until the advent of the laser in the 1960s, and the revolution in Charged
Coupled Detector (CCD) arrays in the 1980s and 1990’s added to the benefits of
high laser source intensities. In addition, the development of narrow band laser
line rejection filters meant that the huge losses in signal from traditional triple
monochromator systems could be overcome with the combination of a filter set
and a single spectroscopic grating. Furthermore, the significant reductions in acquisition time with multichannel signal detection enabled significant improvements in signal to noise ratios [11]. The combination of technology developments
led to a new range of Raman spectroscopic microscopes in the 1990s, establishing
Raman spectroscopic microscopy as a relatively inexpensive benchtop laboratory
tool to rival conventional infrared spectroscopy.
Similar to IR spectroscopy, Raman spectroscopy entails the coupling of incident radiation with molecular vibrations and the resultant Raman spectrum is
characteristic of the compound or material. However, whereas IR spectroscopy involves the absorption of radiation, Raman spectroscopy is a scattering technique,
whereby the incident radiation couples with the vibrating polarisation of the molecule and thus generates or annihilates a vibration. The differing underlying mechanisms gives rise to a complementarity of the two techniques. For a vibration to be
active in IR spectroscopy, a change in dipole is required, whereas to be Raman active, a change in polarisability is required. Vibrations of asymmetric, polar bonds
thus tend to be strong in IR spectra, whereas Raman is particularly suitable as a
probe of symmetric, nonpolar groups. Notably, OH vibrations of water are very
strong in IR spectra, whereas they are extremely weak in Raman spectra, rendering Raman a potentially more suitable technique for bioapplications.
A further implication of the differing physical origins of the techniques is that
whereas IR monitors the absorption of IR radiation, Raman scattering can be employed in the UV, visible or near IR regions of the spectrum. Raman scattering
thus offers intrinsically higher spatial resolution for mapping or profiling, the diffraction limit being determined by the wavelength (<1m for Raman, ~5-10m
for IR). For many applications, however, near IR is favoured as a source for Raman analysis, to minimise interference from scattering, fluorescence, or photodegradation of the sample [12].
FTIR has become an accepted tool in biophysics for analysis of the structure
and interactions of proteins [13], lipids [14], carbohydrates [15] and nucleic acids
[16]. Applications to tissue samples for (cancer) diagnostic applications were first
reported in the early 90s [17], and since this time a range of pathologies has been
investigated [18 – 20]. The application of Raman spectroscopy to biomolecules
and even tissues was first demonstrated as early as the 1960s [21-23] and by the
mid 1970s biomedical applications were explored [24]. Whole cell and tissue studies have been carried out on a range of pathologies [25-29] and in vivo studies [3032] have demonstrated the prospective for diagnostic applications. The potential
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of vibrational spectroscopy in conjunction with multivariate analysis techniques as
a diagnostic tool has thus been well demonstrated and the concept of Spectral Cytopathology has been coined [33].
This chapter is based on the experience of the research activities within the Focas Research Institute, Dublin Institute of Technology, and outlines efforts and
progress in the applications of both Raman and infrared spectroscopy for the routine screening of disease as well as the understanding disease origin. It further describes studies demonstrating the potential of the techniques for in vitro diagnostics and biochemical analyses, for example of the efficacy of chemotherapeutic
agents and the interaction of nanoparticles in cells.
Vibrational Spectroscopy for Cervical Cancer Pathology [34]
Cervical cancer is the second most common cancer among women worldwide
and generally is more common in developing countries. However, substantial decreases in cervical cancer mortality have been observed in Western countries and
some developing countries with well developed screening programmes [35]. A
Papanicolaou test (Pap smear test) is used to screen for Cervical Intraepithelial
Neoplasia (CIN) and cervical cancer in the general female population. Such cervical cytology can have a high specificity of 95-98% but a sensitivity of lower
than 50% [36]. Other methods such as automated cytology and human papilloma
virus (HPV) testing [37-39] have been introduced to reduce the false negative
rates. An abnormal Pap smear is followed by colposcopic examination, biopsy
and histological confirmation of the clinical diagnosis. This involves the visual
examination of histological sections. The grading characteristics are quite subjective and pre-malignancy may not be visually perceptible at all.
Optical technologies such as fluorescence spectroscopy [40], polarised light
scattering spectroscopy [41], optical coherence tomography [42, 43] and confocal
reflectance microscopy [44] have emerged in recent years as promising tools for
diagnosis of cervical and other cancers. The potential of vibrational spectroscopy
for cervical cancer diagnosis has also been recognised. A number of studies have
shown that Fourier Transform Infra Red (FTIR) spectroscopy [45-47] or Raman
spectroscopy [32, 48] can be used for detecting spectral changes in malignant and
pre-malignant cells. Raman spectroscopy is, however, more suited to in vivo studies because of minimal interference from water. Coupled with adapted multivariate analysis techniques, Raman spectroscopic analysis of cervical biopsies and cytological samples can provide high specificity and sensitivity for the detection of
cervical cancer and early pre-malignant states. The following provides an illustration of such applications combining Raman analysis and Principal Component
Analysis/Linear Discriminate Analysis [34].
Formalin fixed paraffin preserved (FFPP) cervical tissue samples were obtained
from the National Maternity Hospital, Holles St., Dublin. Two parallel 10μm
FFPP sections were cut from each block using a microtome, mounted on glass
slides and dried. Samples were dewaxed in-house prior to investigation by immersion in baths of Xylene (BDH), Ethanol Absolut (Merck) and Industrial Methylat-
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ed Spirits 95% (Lennox) and air-dried. Cervical tissue was dewaxed using the
same procedure outlined above, but xylene was substituted with hexane, due to the
improved level of dewaxing [49]. One section from each sample (the reference
section) was stained with Haematoxylin and Eosin and the other kept unstained for
spectroscopic examination.
FFPP cervical tissue sections were characterised by consultant pathologist Dr.
P. Kelehan, National Maternity Hospital, Holles St., Dublin, and the samples consisted of 20 normal and 20 invasive carcinoma sections from 40 individuals. Of
the 20 carcinoma samples, 10 samples were identified as having various grades of
CIN, which were also marked for examination.
An Instruments S.A. Labram Raman spectroscopic confocal microscope was
used, with an Argon Ion laser operating at an excitation wavelength of 514.5nm. A
x50 objective lens was used. The laser power at the sample was measured and
found to be 6.5±0.05mW, focused to a spot size of 2μm at the tissue surface.
Raman spectra of the various tissues were accumulated for 150 seconds. A total
of 10 spectra were recorded from different spots on each sample.
Selected spectra were baseline corrected, dark current subtracted and were
smoothed using a 10 point moving average before being normalised to the spectral
maximum, from 0 to 1. Basic matrix manipulations and data reduction was carried
out in Microsoft Excel Professional 2003 (v. 11.0), before being exported into
Minitab to perform Principal Component Analysis (PCA) and Linear Discriminant
Analysis (LDA). Minitab Release 14.1 Statistical Software Analysis Programme
was used to produce PCA scores and LDA plots, as well as to carry out leave-oneout cross validation.
Figure 1 shows the layer structure of normal cervical tissue in an unstained
FFPP tissue section together with the Raman spectra recorded from basal cells, epithelial cells and connective tissue. The spectra of the three different regions do
have a degree of similarity, but notably there are many differentiating spectral features. The spectra of basal cells show strong bands at 724 cm-1, 779 cm-1 and 1578
cm-1 which are characteristic of nucleic acids. The morphology of basal cells consists of a single line of tightly packed cells, with large nuclei in relation to the
compacted surrounding cytoplasm. In addition, these cells are constantly dividing,
providing cells to the parabasal layer. For both of these reasons, a high concentration of DNA would be expected in the basal cells. Spectra of epithelial cells have
characteristic glycogen bands at 482 cm-1, 849 cm-1, 938 cm-1, 1082 cm-1 and 1336
cm-1. Collagen contributions can be clearly seen in the spectra of connective tissue
at 850 cm-1, 940 cm-1 and 1245 cm-1.
Figure 2a compares the Raman spectra collected from normal epithelial cells and
invasive carcinoma from a selection of different patients. Glycogen contributions
are clearly visible in the spectra from the normal epithelial tissue. The most obvious bands arise at 482 cm-1, 849 cm-1 and 938 cm-1 and are due to glycogen skeletal deformation, CCH aromatic deformation and CCH deformation respectively.
However, there are also other glycogen contributions not as apparent, including a
CC stretching band at 1082 cm-1 and CH3CH2 wagging at 1336 cm-1. These glycogen bands (482 cm-1, 849 cm-1 and 938 cm-1) are absent in the spectra from inva-
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sive carcinoma, and a reduction in the intensity of the CC stretching mode (1082
cm-1) is also apparent. Glycogen, a polysaccharide, is the principal storage form of
glucose. Cervical cells are unusual among other epithelial cells in that they accumulate large amounts of glycogen during the maturation process. Glycogen is
known to be linked with cellular maturation and disappears with the loss of differentiation during neoplasia. The spectra of invasive carcinoma also show characteristic nucleic acid bands. These include prominent bands at 724 cm-1, 779 cm-1 and
1578 cm-1, but also at 829 cm-1, 852 cm-1, 1002 cm-1, 1098 cm-1, 1240 cm-1. Distinct bands are also seen at 1366 cm-1, a shoulder at 1484 cm-1 and a band at 1578
cm-1. An increase in the intensity of the Amide I band (1655cm-1) was observed in
the spectra of carcinoma samples compared to the normal tissue samples. The increased nucleic acid and protein bands are a result of the increased proliferation of
these tumour cells.

Figure 1: (a) Photomicrograph of unstained tissue section, with different cell types
identified and (b) Raman spectra recorded from basal cells (A), epithelial cells (B)
and connective tissue (C) in cervical tissue sections. The main spectral features associated with each cell type are highlighted. (Reproduced from [34])

Figure 2:Raman spectra of a) normal cervical epithelial cells (A) and invasive carcinoma cells (B) and (b) Raman spectra of CIN tissue. Assignments of the main
Raman vibrational modes are detailed in table 1. (Reproduced from [34])
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Figure 3: Linear discriminant analysis of the principal components of the first derivative, normalised, 10 point averaged spectra, over the entire spectral range, C =
CIN, N = normal and T = invasive carcinoma. (Reproduced from [34])
To investigate whether pre-malignant changes can be elucidated using Raman
spectroscopy, 10 areas of CIN from 10 different patients were marked by the
pathologist and a selection of the resulting Raman spectra are shown in Figure 2b.
A number of the spectral features identified in the invasive carcinoma samples
were also observed in the CIN samples such as the nucleic acid bands at 724 cm-1,
779 cm-1, 852 cm-1, 1366 cm-1 and 1578 cm-1. This indicates that biochemical
changes associated with CIN can be identified using Raman spectroscopy.
Principal component analysis (PCA) is a method of multivariate analysis widely used with datasets of multiple dimensions. PCA is a chemometric technique
that can resolve a complete spectral data set into a few principal components and
can thus identify and isolate important trends within the data set [50]. It allows the
reduction of the number of variables in a multidimensional dataset, although it retains most of the variation within the dataset. The order of the PCs denotes their
importance to the dataset. PC1 describes the highest amount of variation, PC2 the
second greatest and so on. Therefore, var (PC1) ≥ var (PC2) ≥ var (PCp), where var
(PCi) represents the variance of PCi in the considered data set. Generally, the 3
first components represent more than 90% of the variance. This statistical method
was preferred for this study to highlight the variability existing in the spectral data
set recorded during the different experiments. Another advantage of this method is
the observation of loadings which represent the variance for each variable (wavenumber) for a given PC. Analysing the loadings of a PC can give information
about the source of the variability inside a data set, derived from variations in the
molecular components contributing to the spectra.
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Peak Position
(cm-1)
622
642
670
720
724
746
750
782
827
832
854
873
922
935
1004
1031
1034
1065
1093
1096
1098
1102
1124
1128
1155
1175
1208
1214
1220-1280
1236
1240
1311
1314
1337
1335
1340
1366
1440
1450
1484
1548
1578
1583
1585
1550-1700
1602
1618
1660 - 1665
2930
2932

Assignment
C-C twisting (Proteins)
C-C twisting mode of Tyr and Phe
C, T,G (DNA/RNA)
C-N stretching in A and lipids
CH2 deformation
CH2 rocking
Symmetric ring breathing (protein)
U, T, C (ring breathing modes in the DNA/RNA)
PO2 stretching in DNA, Tyr
CCH deformation aliphatic
Ring breathing in Tyr and Pro (proteins)
CC stretch
C-C stretching
C-C stretching mode of Pro and Val
CC aromatic ring breathing
C-H bending mode in Phenylalanine
C-N stretching in proteins
C-N stretch
symmetric PO2 stretching of the DNA backbone; lipids
C-C chain stretching
CC stretch
CC stretch
CC skeletal stretch trans
C-N stretching in proteins; C-O stretching in
carbohydrates
C-C and C-N stretching of proteins
C-H in plane bending mode of Tyr and Phe; C, G
C-C6H5 stretching mode in Trp, Phe;
CC stretch backbone carbon phenyl ring
Amide III; A,C,T ring breathing modes of the DNA/RNA
CN stretch, NH bending Amide III band
CN stretch, NH bending Amide III band
CH3/CH2 twisting mode of collagen and lipid
CH deformation
CH2 deformation
CH2 deformation
G (DNA/RNA), CH deformation in proteins and
carbohydrates; Trp
CH2 bending
CH2 scissoring
CH (CH2) bending mode in proteins and lipids
CH2 deformation
NH deformation; CN stretch Amide II band
C=C olefinic stretch
A,G (DNA/RNA); C=C bending mode of Phe
C=C stretching
H2O bending mode
CO stretching
C=C Phe, Tyr and Trp
C=O stretch Amide I α-helix
CH2 stretching (2930 cm-1)
CH3 symmetric stretch (2932 cm-1).

Peak reference (figure
4)
1
2
3
4

5
6
7
8

9
10
11
12

13
14
15
16
17

18

19

20

21
22
23
24

Table 1: Peak position and assignments of main Raman vibrational modes
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Predicted (Raman)
Normal
CIN
Invasive carcinoma

Diagnosis (Histopathology)
Normal
CIN
Invasive carcinoma
198
0
0
0
99
3
2
1
195

Total
Number correct
Proportion

200
198
0.990

100
99
0.990

198
195
0.985

Sensitivity
Specificity

99.5%
100%

99.0%
99.2%

98.5%
99.0%

Table 2: Summary of cross-validation classification results and sensitivity and
specificity values
Principal component analysis was used to reduce the number of parameters
needed to represent the variance in the spectral data set. The principal components
were then used to generate a linear discriminant model. LDA applies a linear discriminant function that maximises the variance in the data between groups and
minimises the variance between members of the same group [51]. All three tissue
classes were successfully discriminated as shown in figure 3. The classification
model was tested using a leave one out cross validation in which all but one spectrum was used to build the model. This model was then used to predict the remaining spectrum. This was repeated for all 498 spectra and the results are shown in
table 2. Of 498 tissue spectra, 492 were correctly classified as normal, invasive
carcinoma or CIN. The cross validation mis-classified 6 spectra, 2 of which were
normal samples assigned as invasive carcinoma. The other 4 were either invasive
carcinoma or CIN mis-classified as either CIN or invasive carcinoma respectively.
Importantly, no abnormal samples were classified as normal. Based on the cross
validation results, sensitivity and specificity values were calculated as 99.5% and
100% respectively for normal tissue, 99% and 99.2% respectively for CIN and
98.5% and 99% respectively for invasive carcinoma. It is possible that these values may be slightly over optimistic because of the LDA method used with leave
one out cross validation. However, similar methods have been used previously to
classify bladder and prostate cancer [52], breast cancer [53] and basal cell carcinoma [54]. Ideally, the use of an unknown test set would provide a more robust
analysis of the sensitivity and specificity of the technique and this is planned for
future work.
The results show the ability of Raman spectroscopy to classify cervical cancer
and pre-cancer with high sensitivity and specificity. These classifications are
based on biochemical changes known to accompany cervical cancer such as loss
of differentiation and increased proliferation. The study presented details of the
application to cervical biopsies, but they can equally be applied to cytological
samples. Studies in a range of different pathologies have emerged and technologi-
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cal development is progressing beyond the stage of “proof of concept” [55, 56].
Technologically, ex-vivo screening of histological or cytological samples is less
challenging, but as the technologies are optically based, the emergence of in-vivo
probes is inevitable [57]. The development of ssuch an automated technique
measuring biochemical changes with improved diagnostic capability could allow
faster, more effective patient management and inevitably would increase survival
rates. Raman spectroscopy therefore offers enormous potential as a ‘next generation’ technology to assist pathologists and cytologists with cervical cancer, and
other pathological screening and diagnosis.
In the development of the technologies towards clinical and other applications,
it is important to ensure that the preprocessing of the spectral data is appropriate
and in this context it is important to understand the physical and instrumental
origin of any measurement artefacts. Significant progress has been made in FTIR
spectroscopy to identify and correct for so-called dispersion artefacts [58-60]. In
Raman microspectroscopy, it has been demonstrated that measurement in immersion significantly reduces the spectral background [61] and photodamage [62],
minimizing the need for spectral preprocessing.
Notably, the analytical capabilities of the spectral techniques rely heavily on
multivariate analytical techniques to classify the complex spectral signatures, and
changes to them, associated with disease. A broad range of data analytical techniques are available including Genetic algorithms, Support Vector Machines, Neural Networks etc. To date, no direct comparison of the efficacy or suitability of
such techniques has been made and such a comparison on experimental data may
not be conclusive, as the true result is not known. Ultimately, the field would benefit from an exhaustive comparison of the range of data preprocessing and analysis
techniques on appropriate simulated datasets [59].
Exploring the aetiology of disease – HPV infection [63, 64]
The probability of developing cervical dysplasia is much higher for women infected with the human papillomavirus (HPV) than those free of infection [65]. Infection with oncogenic or high- risk HPV (HPV-16, HPV-18) is the main risk factor for cervical cancer [66], 99.7% of invasive cervical neoplasia being associated
with HPV infection [67]. Identifying the presence of HPV is a very important factor in the prevention of cervical cancer and thus, HPV testing has been added to
the range of clinical options for cervical cancer screening. HPV testing is based on
detecting the DNA of the virus. It has been found that the DNA of high risk strains
of HPV is assimilated within the cellular DNA of the host [68]. A drawback to
HPV testing is that it is more expensive and time-consuming than other screening
tests, and it requires a sophisticated laboratory infrastructure.
Raman spectroscopy has also been used to study cell lines derived from the
cervix, revealing spectral variations, mostly in peaks originating from DNA and
proteins, in cell lines expressing the E7 gene of HPV-16 compared to cells not affected by HPV [69]. Furthermore, it has been demonstrated that in low-grade cytology infected with high-risk oncogenic HPV16 or HPV18, it was possible to dif-
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ferentiate samples from women based on whether they were aged 20–29 years vs.
30–39 years using attenuated total reflection infrared spectroscopy [70].
To further demonstrate the potential of vibrational spectroscopy for clinical
screening, four cervical cancer cell lines were investigated using both Raman and
FTIR spectroscopy; HPV negative C33A, HPV-18 positive HeLa with 20-50 integrated HPV copies per cell, HPV-16 positive SiHa with 1-2 integrated HPV
strands per cell and HPV-16 positive CaSki containing 60-600 integrated HPV
copies per cell. The main aim of the experiment was to investigate biochemical
changes in cells caused by high risk HPV strands (HPV-16 and HPV-18) and to
examine whether it is possible to differentiate between the cells with no HPV copies and cells infected by low number, medium number and high number of integrated HPV copies, using vibrational spectroscopic techniques. Both common
forms of vibrational spectroscopy, Raman and Fourier Transform Infrared absorption, were used to gain complementary information [63]. The Raman spectroscopic analysis is discussed here.
A Horiba Jobin Yvon LabRam 800HR was employed for the measurement, operating at a wavelength of 532nm and utilising a x100 objective. After incubation,
cells were centrifuged to form pellets and washed thoroughly before measurement.
The mean of 30 Raman spectra recorded from two pellets (approximately 15 spectra per pellet) for C33A, SiHa, HeLa and CaSki cell lines were derived from the
raw spectra via the pre-processing procedures and are presented in figure 4. Assignments of the main peaks (numbered in figure 4) are shown in table 1. In the
mean Raman spectra, almost no significant differences between HPV negative
C33A and SiHa cells, containing 1-2 HPV copies per cells (low HPV concentration) are discernible. Only the peak at 1583cm-1 assigned to DNA/RNA and Phenylalanine vibrations was found to vary between C33A and SiHa cells. For cells
containing a higher number of integrated HPV copies per cell, HeLa cells (medium HPV concentration) and CaSki cells (high HPV concentration), the observed
differences are more prominent for protein, nucleic acid and lipid vibrations.
CaSki cells exhibited a significant increase in Amide I (proteins) intensity at
1660cm-1 and a decrease in lipid levels at 1093cm-1, 1311cm-1 and 1450cm-1 compared to C33A, SiHa and HeLa. HPV presence in a cell appears to change protein
expression, which may result in the protein variations observed in the Raman
spectra, primarily for the Amide I region. Further differences in protein vibrations
between the cells affected by non- and low HPV number compared to medium and
high HPV number were observed in the Amide III region (1254cm-1), and protein
constituent amino acids Tryptophan (Trp), Proline (Pro), Tyrosine (Tyr) and Phenylalanine (Phe) vibrations at 854cm-1, 935cm-1, 1003cm-1, 1583cm-1 and 1618cm1
. Variations in vibrations associated with nucleic acid constituents: PO 2 group, A,
C, T, U at 1093cm-1, 720cm-1, 782cm-1, 1254cm-1, 1583cm-1 respectively were also observed. The differences in protein and nucleic acid composition support the
molecular data which demonstrates intergration of HPV DNA at chromosome
fragile sites and the subsequent downstream effect of HPV E6 and E7 oncoprotein
expression on host cell proteins such as p53 [71].
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The principal component (PC) scatterplot for Raman spectroscopic results presented in figure 5A shows a distinctive separation between the cell lines, suggesting a HPV concentration dependence factor. The C33A (non HPV) and SiHa (low
HPV concentration, LC) cell lines are grouped together, confirming observed similarities between these two types of cells based on mean spectra analysis. The
HeLa (medium HPV concentration, MC) and CaSki (high HPV concentration,
HC) cell lines are clearly separated from each other and from the C33A-SiHa
group. Although the 3D PCA scatterplot demonstrates the HPV concentration dependent separation, the cell lines are not grouped according to increasing (or decreasing) number of HPV copies. CaSki (HC) cells lie between HeLa (MC) and
SiHa (LC). This suggests the influence on the data point distribution of another
factor – HPV strand type. HeLa are cells infected by HPV-18, while CaSki and
SiHa are infected by HPV-16. Principal component loadings are presented in figure 5B. Peak numbers correspond to assignments presented in table 1. The percent
of variance explained by PC1, PC2 and PC3 is 71.9%, 10.8% and 6.2%, respectively. The first principal component is dominated by the contribution of the H-OH bending of water, a broad peak in the range of 1550-1700cm-1 with maximum at
~1644cm-1 [72]. Water is not, however, the only potential contribution within this
range, as Amide I vibrations (β-sheet) exhibit a maximum at 1640cm-1. Nucleic
acid contributions to PC1 may also be present at 782cm-1, 1093cm-1 and 1583cm-1,
although it is very difficult to judge what is the percentage of contribution of each
of these components. The second principal component shows predominantly protein and lipid contributions. Lipids are exhibited at 1095cm-1, 1310cm-1 and
1450cm-1, while proteins are at 1660cm-1 – Amide I (α-helix), 1270cm-1 - Amide
III (α-helix), 1450cm-1, C=C Phe at 1582cm-1 and Trp at 750cm-1. The third principal component contains a lot of biological information with mainly nucleic acid
and protein contributions but only accounts for 6.2% of variance. There are distinctive peaks corresponding to nucleic acids and protein vibrations. DNA and
RNA contributions are observed at 670cm-1, 720cm-1, 782cm-1, 1092cm-1,
1250cm-1, 1340cm-1 and 1583cm-1. PC3 shows a strong influence of variation arising from protein vibrations, Phe (642cm-1, 1002cm-1, 1031cm-1, 1583cm-1 and
1618cm-1), Trp (1208cm-1, 1340cm-1 and 1618cm-1), Tyr (642cm-1, 854cm-1 and
1618cm-1), Pro (854cm-1, 935cm-1), Val (935cm-1), Amide I at 1680cm-1 (disordered) and Amide III at 1260cm-1 (disordered). The source of variations shown in
the loadings is in very good agreement with those observed in the analysis of the
mean spectra for the investigated cell lines. The main peaks in the loadings arise
from protein, nucleic acid and lipid component vibrations. Each principal component is dominated by different cellular components; water, and possibly nucleic
acids and proteins in PC1, lipids and proteins in PC2 and nucleic acids and proteins in PC3. Amide I and Amide III contributions are present in all principal
component loadings indicative of differences in structural conformation of the
protein β-sheet in PC1, α-helix in PC2 and disordered conformation in PC3. As
mentioned previously, variations in protein, nucleic acid and lipid levels arise
from the fact that the viral DNA interacts with the cellular DNA, causing repro-
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gramming of protein expression in the cell. It was noted that the multivariate analysis could be sustantially influenced by water contributions in the region of
1640cm-1. Repeated over the spectral range 400-1550cm-1, the PCA gave a similar
separation of the cellular types and yielded similar principal components.
The applications of spectroscopic analysis, coupled with multivariate statistic
techniques can therefore be extended beyond diagnosis based on classification to
biochemical analysis of the underlying physiology based on changes to the molecualr composition on a cellular and subcellular level. This new technology for cervical screening not only can distinguish cervical cells based on biochemical content but also can elucidate the effect of HPV on the cells. As a further
demonstration of the potential of the techniques, FTIR spectroscopy was employed to further explore the known manifestations of HPV infection in cervical
cell lines [64].

Figure 4: Mean Raman spectra of cervical cancer cell lines. (Reproduced from
[63])
Differentially expressed proteins in cancer have potential utility as biomarkers.
As the cell cycle is often disrupted in a cancerous cell, proteins associated with it
are often candidate biomarkers. Putative biomarkers of cervical cancer that are
currently under study include proteins such as CDC 6 (DNA licensing protein),
minichromosome maintenance proteins (MCM 2, MCM 5), p53 or p16 INK4A [73].
These biomarkers have been used to detect the presence of abnormal cells, based
upon immunocytochemical methods. p16INK4A regulates the levels of active cyclin
D/CDK in the cell, providing a feedback mechanism that regulates the levels of
MCM (minichromosome maintenance proteins), PCNA (proliferating-cell nuclear
antigen) and cyclin E. Overexpression of p16 INK4A, which is considered a marker
of elevated E7 expression, can be detected in some CIN1 lesions, as well as in
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CIN2 and CIN3 lesions that show evidence of integration [74,75]. Integration of
the HPV genome into the host cell chromosome is a critical event in the development of most cervical cancers [76]. Overexpression of p16 INK4A has been demonstrated in cervical cancers as a result of functional inactivation of pRb by the HPV
E7 protein [77]. This overexpression highlights the potential of p16 INK4A as a
marker for CIN and cervical cancer. HPV positivity and p16INK4A positivity have
shown a correlation, even though p16INK4A expression was also seen in a limited
number of HPV negative biopsy samples [78]. Also, a correlation between
p16INK4A expression and cervical lesion grade and HR-HPV positivity has been
documented [79]. p16INK4A has been proven to be the most reliable marker of cervical dysplasia and was found to mark all grades of squamous and glandular lesions of the cervix. The use of p16INK4A immunocytochemical analysis as a complement to conventional screening programmes could potentially aid in the
reduction of false positive and false negative results [80].

Figure 5: Principal component analysis for Raman spectroscopy results for cervical cancer cell lines. (A) - Three dimensional PCA scatterplot. Graphs show
separation of the cervical cancer cell lines suggesting HPV concentration dependence. (B) - Principal component loadings. Peak assignments correspond to those
listed in table 1. (Reproduced from [63])
In the first part of this study, expression of p16 INK4A was analysed in cervical
cancer cell lines using immunocytochemical staining and both confocal fluores-
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cence microscopy and flow cytometry. [64] Fluorescence images of cells were
collected using a confocal fluorescence microscopy system. Representative images of cells are presented in figure 6, where A, C, E and G show only green fluorescence staining (FITC), while B, D, F and H show the overlay of green (FITC) and
red (PI) fluorescence signals. The FITC fluorescence intensity is associated with
the p16INK4A expression level, while the PI dye was used to visualise the position
of nuclei within the cells.

Figure 6: Confocal microscopy images of cervical cell lines: A-B C33A cells,
C-D SiHa cells, E-F HeLa cells, G-H CaSki cells. Images A,C, E and G show
FITC fluorescence staining (related to p16INK4A expression), while images B, D,
F and H present FITC and PI staining. (Reproduced from [64])
A degree of correlation between the number of HPV copies per cell line and the
fluorescence intensity related to p16INK4A expression was observed for the flow cytometry data (figure 7). The highest level of p16INK4A expression (intensity of
staining) was observed for CaSki cells, followed by HeLa, SiHa and the lowest for
C33A. The relationship between p16INK4A expression and HPV copy number illustrated by figure 7 is supported by a study conducted by Klaes et al. (2001), wherein a correlation between increasing grade of cervical lesion and staining intensity
of p16INK4A was observed [81]. Similarly, Agoff et al. showed that p16 INK4A expression correlates with an increasing severity of cervical disease [82]. Murphy et
al. showed a strong correlation between HR-HPV positivity and p16INK4A staining
pattern [78, 83, 84]. In the study conducted by Wang et al. a correlation between
p16INK4A immunostaining and cervical disease severity stratified by HPV status
was observed [85].
The results demonstrate a correlation between p16 INK4A immunostaining and
the presence of HPV in cervical cancer cell lines, supporting the previous studies
and implies that p16INK4A is a highly sensitive marker of HPV in cervical cancer
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cell lines. The hyperbolic-like relationship between the levels of p16INK4A and
HPV copy number is typical of the response of a cell to the action of an agonist
[86] and in figure 7, is approximated by a fit with the following function y=a+b√x
+cx, where a=62.4, b=3.5 and c=-0.1. It should be noted that, in figure 7, the HPV
copy number is represented by the average of the range quoted in literature [87,
88] and so error margins in the horizontal axis are potentially very large. However, the sublinear nature of the plot indicates that p16 INK4A expression levels are
particularly sensitive for low HPV copy number.

Figure 7: Fluorescence intensity related to the p16INK4A expression level in cervical cancer cell lines plotted against the average HPV copy number present in a
cell with the fitted function. The dotted line is a fit of the data with the equation
y=a+b√x +cx, where a=62.4, b=3.5 and c=-0.1. (Reproduced from [64])
FTIR maps were recorded for C33A, SiHa, HeLa and CaSki cells (2-4 maps for
each cell line) using the Perkin Elmer Spotlight 400N system. As in Raman spectroscopy, three main biochemical cellular components feature strongly: proteins,
lipids and nucleic acids. A detailed examination of the relative intensities of peaks
related to vibrations of the cellular components (nucleus and cytoplasm) of the
C33A, SiHa, HeLa and CaSki infrared spectra revealed the following tendencies:
• Increase in nucleic acid levels with increasing number of HR-HPV copies in
the cell or increasing p16INK4A expression (figure 8A, 8D),
• Decrease in lipid levels with increasing number of HR-HPV copies in the cell
or increasing p16INK4A expression (figure 8B, 8E),
• No tendency for changes in protein levels related to HR-HPV copy number or
increasing p16INK4A expression (figure 8C, 8F).
The observed increase in nucleic acid levels may be related to an increased
number of chromosomes present in HPV infected nuclei. It was reported by Mehés et al. that HPV presence facilitates polyploidisation (increase in chromosome
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number in a cell nucleus) in cervical squamous cells [89]. Additionally, it is
known that binding of HPV DNA to host DNA disrupts the normal function of the
cellular proteins and as a consequence, the host cell accumulates more and more
damaged DNA that cannot be repaired [90].

Figure 8: Peak intensity analysis for FTIR spectra of nuclear and cytoplasmic regions of cervical cancer cells. Dependence of peak intensities vs. HPV copy number was fit with y=a+b√x +cx function, while peak intensities vs. fluorescence intensities (p16INK4A expression level) was fit with a linear function, y=a+bx.
(Reproduced from [64])
CaSki cells are known to be the most malignant and in the spectra of the cytoplasm and nucleus representing this cell line the highest level of nucleic acids was
observed. A similar increase of the nucleic acid related peaks in cancerous cervical cells was noticed in previous studies [91, 92] and is confirmed by these observations. Changes in lipid levels are possibly associated with the disruption of the
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membrane functionality caused by the virus which influences lipid rafts [93]. A
similar behaviour was noted and reported in the previous study on cervical cancer
cell lines, wherein both Raman and FTIR (Figure 4) techniques were utilised [63].
Moreover, it was reported previously by Wong et al. that the degree of disorder of
methylene chains in membrane lipids increases in cervical neoplastic cells [94].
The absence of any clear relationship between protein levels and HPV copy number is expected, as the presence of HPV in the cell results in functional over- and
under- expression of only select biomarker proteins [73], while the level of the
other proteins would not be affected. The variation of the spectroscopic features
associated with the nuclear lipids, proteins and nucleic acids as a function of the
HPV copy number was found to be sublinear and to be well fitted with a similar
function to that employed to describe the variation of the p16 INK4A levels with
HPV copy number in figure 7. Notably, the dependences of the cytoplasmic lipids,
proteins and nucleic acids on the p16INK4A levels, as identified by fluorescence
were found to be linear.
In order to further elucidate the multivariate spectral signatures which are specifically related to HPV infection, multivariate regression models were constructed using Partial Least Squares Regression (PLSR) and PLS Jack-knifing was employed as a multivariate feature selection technique [94-96]. The PLSR algorithm
seeks to develop a model that relates the spectral data (X-matrix) to a series of targets (Y-matrix, e.g. concentration of reaction product or analyte) according to the
equation Y=XB+E, where B is a matrix of regression coefficients and E is the regression residual. The PLS Jack-knifing method developed by Westad and Martens [96] was then used to determine the spectral features that were statistically
significant at a particular level of confidence using t-testing of the regression coefficients, B.
Figure 8 demonstrates that p16INK4A levels as measured by fluorescence intensity are approximately linearly correlated with the univariate spectral features and
thus, as PLS is a linear model, these values are employed as targets for the PLS
analysis. The model can therefore be applied to the FTIR data to elucidate multivariate signatures which are correlated to p16INK4A expression level, and therefore,
in accordance with figure 7, to HPV infection levels. Once established, these variation patterns can then be applied to unknown samples to screen for the biomarker
levels. As p16INK4A was found to be predominantly expressed in cytoplasmic regions of the cells, signals recorded from the cytoplasm were utilised in the analysis. Calibration (based on 40% of the data) and test set performance (based on
60% of the data) are presented in figure 9A and demonstrate a very good fit to the
model. As shown in figure 9B, the PLS loading exhibits variations originating
from proteins, primarily as sub-bands of Amide A (3000-3700cm-1) and Amide III
(1230-1250cm-1), and are associated with the chain of biochemical disruption in
protein regulation caused by HPV presence [97]. Another prominent spectral feature differentiating the cell lines, and present in PC loadings and the PLS loading,
is the lipid contribution. Again, the presence of HPV is seen to significantly influence the lipid balance within the cell [93], and thus it can be expected that the vi-
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brations of lipid component groups differentiate cells with various HPV copy
number. This differentiation was distinctly manifest in the mean spectra of the cytoplasm and nucleus (figure 4 – enlarged lipid region of 2800-3050cm-1). Furthermore, the DNA and RNA related peaks are exhibited in the range of 10501250cm-1, (sym. and asym. PO2 str. CO str.) and 3200-3400cm-1.

Figure 9: Partial Least Squares analysis results targeting the p16INK4A expression level prediction based on the FTIR spectral features. (Reproduced from [64])
A potential application of vibrational spectroscopy to cervical cancer screening
and diagnosis requires a full understanding of the spectral information and its correlation with existing screening and diagnostic methods such as Pap testing or colposcopy. However, the field of the cervical cancer recognition and detection is
still developing with new biomarkers [73] being identified that may be considered
as adjuncts to existing cervical cytology and pathology methods. Biomarkers such
as p16INK4A have been found to be useful for low-grade lesions (Benevolo et al.,
2006, Passamonti et al., 2010, Negri et al., 2008, Focchi et al., 2007) making them
particularly attractive. Thus, a correlation and explanation of the spectral information with these new biomarkers is a new challenge for biospectroscopists working on future cancer diagnostic systems. The study outlined above demonstrates
how multivariate regression techniques can help to associate specific spectral signatures with specific biomarkers, potentially paving the way for “spectro-markers”
of disease.
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Analysis of the Effects of Anticancer Agents [98, 99]
The previous sections demonstrate how vibrational spectroscopy, coupled with
multivariate statistical techniques can be utilized for high sensitivity and specificity disease screening, but also to analyse the underlying biochemical changes at a
cellular level. This analytical capability opens up the possibility of a range of in
vitro applications.
For the design of new anticancer drugs, an in-depth understanding of the mechanisms underlying their biological effects is required. The in vitro study of the interaction of anticancer drugs with mammalian cells is therefore important to elucidate the mechanisms of action of the drug on its biological targets and thereby
maximise efficacy and guide development strategies. The prevalence of such studies is likely to increase following the EU Directive (2010/63/EU) on the replacement, reduction and refinement (RRR) of animal experimentation in scientific studies. Vibrational spectroscopy has great potential to explore subcellular biochemical structure as exemplified by its use in studies investigating the
action of various agents on biological macromolecules as well as their interaction
with cancer cells [100-106]. It can provide high content information as it can examine spectral changes in the cell membrane, cytoplasm and nucleus of the target
cells simultaneously and highlight the biochemical interaction of external agents
with the cell or its physiological response [98, 99]. Validation of the technique of
Raman spectroscopy in the quantitative measurement of the biochemical and
physiological effects of known chemotherapeutic agents is required, however, before it may be used for studies of novel chemical treatments. The study of the
spectroscopic signatures of the biochemical effects of commercially available anticancer drugs may be helpful before application for the evaluation of the novel
anticancer agents.
Cisplatin (cis-Diamminedichloroplatinum (II)) is a well established chemotherapeutic agent with a known mode of action. In the nucleus, it binds with DNA
forming inter-strand and intra-strand crosslinks which lead to cell cycle arrest and
apoptosis [107]. The formation of inter-strand and intra-strand crosslinks between
cisplatin and DNA leads to conformational changes of the DNA. To understand
the changes caused in DNA conformation due to the adducts formed by cisplatin,
the formation of 1,2-GG or 1,3-GTG intra-strand cross-links and their characterization by Raman spectroscopy has been carried out [108] and it was found that 1,3
GTG cross linkages induce more distortion in the B-form DNA as compared to the
1,2-GG complex.
Cancer cell lines, such as the A549 human lung adenocarcinoma cell line provide a good in vitro model for lung cancer. The high spatial resolution of Raman
microscopy can be employed to identify localized spectroscopic changes in the
nucleus, cytoplasm and cell membrane and the responses can be correlated with
drug dose, as well as physiological response, as determined by the cytotoxicological assay MTT. Feature selection techniques can then be used to identify regions
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of the spectrum that are associated with the biochemical effect of exposure to the
agent, and with the subsequent cytotoxicological response of the cells.
The MTT assay is a measure of the mitochondrial metabolic activity and can be
used initially as a standard against which to map the spectroscopic response of the
cells. Maximum cytotoxicity was observed after 96hrs exposure and thus this time
period was employed for all measurements. The cytotoxicity induced in A549
cells due to the exposure to cisplatin for 96hrs, as determined by the MTT assay,
is shown in Figure 10, where the level of viability in each sample was normalised
to that in the control sample. Due to the action of the drug, the mitochondrial activity decreases monotonically which in turn leads to a decrease in cell viability.
The Inhibitory Concentration (IC50) value was derived from the data by a fit of
f(x) = min + (max-min)/(1+(x/IC50)^n) and found to be 1.2 ± 0.2μM, which is
consistent with the literature. For A549 cells exposed to test drug concentration
(TDC) for 72 hrs, IC50 values of 3.59 μM and 2.2 μM are reported elsewhere with
MTT and ATP assays respectively [109]. Also, Cordes et al. have determined an
IC50 value of 2.0 μM for cisplatin (0.1-50 μM) exposed A549 cells using the colony formation assay [110].
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Figure 10. A549 cell viability (measured by MTT absorption) at 96 hours after exposure to Cisplatin. Error bars denote the standard error on the mean at each concentration. (Reproduced from [98])

21

Figure 11: Feature selection in PLSR of Raman spectra of the A549 nucleus
against (A) cisplatin concentrations and (B) against cellular viability. The shaded
areas denote statistically significant features selected using PLS Jack-knifing with
a t-test (p<0.001) of regression coefficients (shown in red with associated standard
error). (Reproduced from [98])
While some indication of the localised biochemical impact of the external agent
can be gleaned from the mean spectra of the cellular regions [98], the spectral
changes are multivariate and may have complex exposure dependence. They include the fingerprint of the interaction of the cisplatin with the nuclear DNA, but
also evident are a multitude of other changes associated with exposure and changes in cellular physiology. In an effort to identify the most important spectral features, feature selection was performed using the PLS – Jack knifing analysis described earlier. The regression co-efficients were obtained forseparate regressions
against cisplatin concentrations and against cell viability with the nuclear spectral
data. To elucidate spectral changes that are most statistically significant with respect to regression against either endpoint, a t-test (p<0.001) was applied on the
PLS-Jack knifing results. The spectral features identified by this process are highlighted by vertical bands in Figure 11.
The PLS regression of the nuclear data against cisplatin concentration (Figure
11A), identifies many features but, for the purpose of this discussion, only the
changes which are related to the known action of cisplatin are highlighted. Features identified include the thymine (737-742 cm-1, 1589-1595 cm-1), guanine
(1548-1553 cm-1) and adenine (1578 cm-1, 1604-1611 cm-1) bands. The regression
co-efficients of guanine and thymine are stronger than that of adenine, indicating
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that cisplatin binds preferably with guanine as compared to adenine [111]. Another interesting observation is that the bands at (877-883 cm-1) and at (899-900 cm1
), both assigned to deoxyribose ring breathing, are significantly changed, indicating a change in the conformation of B-form DNA [112-114]. Changes in the Raman bands of the proteins are also highlighted, as indicated by the regression coefficients which can be assigned to tryptophan ring breathing (761-765 cm-1),
(889-891 cm-1), C-N stretching (1128-1132 cm-1), C-H deformation (1315-1316
cm-1, 1351-1354 cm-1), amide-I (1668-1679 cm-1). These changes may indicate
some structural changes in the nuclear proteins. The spectroscopic features selected by the PLS regression against drug concentration are consistent with the known
direct interaction of the drug with the DNA and thus are identified as spectroscopic markers of the direct chemical interaction of the drug.
The regression against cell viability (Figure 11B), shows the features which are
correlated with the change in cell physiology. These include the conformational
changes of the DNA B-form (832-833 cm-1) and DNA A-form (798-813 cm-1).
These changes in the Raman bands of the DNA can be taken as markers for the
conformational changes in the DNA caused by cisplatin binding to the guanine
and thymine DNA bases(Vrana et al., 2007) and also confirm the observations
from the mean difference spectra. Changes related to protein secondary and tertiary structures are indicated by the selection of amide-III random coil (1225-1228
cm-1), amide-III -sheet (1250-1259), amide-III  helix, tryptophan ring breathing
(711-721 cm-1, 758-763 cm-1, 767-772 cm-1) and phenyl ring stretching modes
(1202-1210 cm-1) together with the C-C skeletal vibrations (935-937 cm-1, 11591163 cm-1), C-N stretching vibrations (1065-1068, 1073-1075) and C-H bending
(1178-1182 cm-1) (1185-1186 cm-1). These features suggest changes in the Raman
bands of proteins and are indicative of structural alterations associated with protein activation and denaturation during cellular apoptosis and nucleic acid repair
responses.
Comparing the regression co-efficients obtained via spectral regression against
cisplatin concentration (which highlight the primary biochemical effect of the action of the agent) with those obtained via regression against cell viability (which
highlight biochemical markers of the change in the viability of the cell), very different spectral features are selected as being statistically significant and thus allow
the differentiation of the chemotherapeutic response. The spectral features of thymine (737-742 cm-1, 1589-1595 cm-1), guanine (1548-1553 cm-1) and adenine
(1578 cm-1, 1604-1611 cm-1) emerge as prominent as a result of regression against
the concentration of the chemotherapeutic agent and are attributable to direct binding of the cisplatin molecule with these DNA bases. In addition, changes related to
proteins feature in the regression against the concentration of the chemotherapeutic agent are significantly different than those changes of protein associated bands
which appear as a result of regression against the cellular viability. The changes in
the features of the proteins due to the chemical effect are attributable to structural
alterations in nuclear histone proteins due to cisplatin interactions with the cellular
DNA. These features are not selected as being statistically significant by the anal-
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ysis for regression against the viability endpoint, suggesting that they are markers
of the biochemical interaction between cisplatin and DNA. Contrastingly, the conformational changes to the DNA A-form (798-813 cm-1) and DNA B-form (832833 cm-1), among the changes associated with the protein features, especially the
amide-III random coil (1225-1228 cm-1), amide-III -sheet (1250-1259), amide-III
-helix, among others, are selected as being statistically significant in the regression against cellular viability, suggesting that they are markers of this physiological endpoint in the chemotherapeutic response. Overall, Figure 11 demonstrates
that the Raman spectrum of the cell may be resolved into distinct groups of statistically significant spectral markers for distinct types of effect. A similar analysis
of the spectral changes as a result of the action of the chemotherapeutic agent in
the cytoplasm and cell membrane can be performed [99]. Raman microspectroscopy can therefore clearly fingerprint the effects of the interaction of the chemotherapeutic agent with DNA, and identify that fingerprint within the sub cellular
spectra of exposed cells.

Figure 12: Calibration (A) and test set performance (B) in prediction with PLSR
of the cell viability using Raman spectra of the nucleus of A549 cells. Root mean
squared errors of calibration (RMSEC) and prediction (RMSEP) are in units of
cell viability, which themselves are normalized to the level in the control. (Reproduced from [98])
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PLSR models of A549 nuclear spectra versus concentration and reference viability measurements from the MTT assay can then be constructed to determine the
ability of the spectral data to predict the level of exposure to cisplatin and the associated level of physiological effect from Raman spectra. All spectra were compiled into a matrix, and were randomly sorted. A total of 60% of the spectra were
used to train the PLSR model and 40% of the total was retained as an independent
test set to assess the performance of the model in predicting the level of exposure,
and the cellular viability, with unseen data. Leave-one out cross validation with
the calibration set was used to determine the optimal model complexity for use in
testing [115]. This process was performed on fifty separate occasions, with randomization of the data matrix and splitting of the data on each occasion to prevent
data bias [116]. The results of prediction of levels of cellular viability is shown in
Figure 12, for the example of the nuclear region, where the values of the root
mean square error of calibration (RMSEC) and the root mean square error of prediction (RMSEP) denote the prediction uncertainty. The mean values of the
RMSEC and RMSEP for the PLSR for prediction of the level of exposure to cisplatin were found to be 1.67 M (0.45) and 3.41 M (0.41) respectively, where
the figures in brackets denote the standard deviations of these estimates. The associated values of RMSEC and RMSEP for PLSR against normalized cellular viability were 0.05 (0.008) and 0.11 (0.011) respectively. The RMSEP for prediction of
cisplatin concentration is therefore 6.8% over the full scale range (0 to 50 M),
and 11% over the full scale range of viability (from 0 to 1). The proportionally
higher observed errors of prediction of cell viability may be due to the development of cellular resistance to cisplatin over the exposure period in the low dose
groups [117, 118], which contributes to a non-linearity in the variation in viability
with concentration that is difficult for the PLSR algorithm to model.
The study demonstrates the potential of commercially available benchtop Raman microscopy for the examination and prediction of chemotherapeutic responses. In general, for subcellular resolution, Raman spectroscopy is chosen over infrared spectroscopy due to the intrinsically higher spatial resolution. Furthermore, the
relative insensitivity to water renders live cell imaging of real time exposures a
possibility [119]. Nonlinear optical imaging techniques [120] promise even higher
spatial resolution in the future, but at present such short pulse systems cannot be
considered benchtop techniques.
Cisplatin, a DNA major groove binder [121], was chosen as a model as its
mechanism of action is well characterised. To fully validate the technique, the
study should be extended to other chemotherapeutic agents of known interaction
mechanisms, such as tallimustine, a known DNA minor groove binder, and ethidium bromide, a known DNA intercalator. In this way the spectroscopic signatures
of their interaction can be established and subsequently can act as a database
against which novel chemotherapeutic agents can be evaluated. Ultimately, the
techniques should be validated in tumour tissue.
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Live cell imaging [122]
Raman microspectroscopy presents several advantages for the study of live
cells, combining molecular analysis with optical imaging. In comparison to infrared spectroscopic analysis, the weak contribution from water offers the possibility
to study the cells in an aqueous environment and thus to keep them alive for the
duration of the measurement [101]. The specific information contained in the Raman spectra provides a signature of the samples studied, which can be related to
molecular content or changes to the physiology as a result of external stimuli [123,
124]. The spatial resolution is of the order of 1-2 m, providing access to the subcellular organisation of the cells at a molecular level [125, 126].
Previous studies have demonstrated the capacity of Raman spectroscopy to
map single cells and their subcellular structures. The identification of the subcellular structures such as the nucleus, cytoplasm and mitochondria can be
achieved [127] and chemical maps can be constructed giving information about
the distribution of differentiating molecules such as proteins [128]. However,
these have been performed on chemically fixed cells and it has since been demonstrated that chemical fixation induces significant changes to the biochemistry of
the cell [129, 130]. Ultimately, if subtle changes in metabolism due to for example
chemotherapeutic agents, toxicants, or radiation are to be discerned, live cells
should be studied.
Over the last decade, new models such as collagen gels and more complex multicomponent systems such as Matrigel have emerged, providing the cells a matrix
which more accurately reproduces the extra cellular matrix (ECM) [131-133]. It
has been demonstrated in various studies that the behaviour of cells cultured in
such an environment differs considerably compared to those cultured on traditional 2D surfaces [134]. In terms of cellular viability and spectral quality, collagen
gels have been recently demonstrated to be a substantially improved substrate for
live cells analysis using Raman spectroscopy. The gels provide a 3-D matrix for
cell growth, although it should be noted that the cells are cultured on the surface of
the matrix. As measured using the Alamar Blue cytotoxicity assay, in comparison
to uncoated quartz, a human lung cell line exhibited a 39% increase in viability in
collagen gels whereas as dermal cell line seemed to be more affected by the different substrates and a 285% increase in viability was observed. Furthermore, after
polymerization, the density of the collagen is too low to give any contribution in
the spectra recorded [119]. Also no contribution from the medium used for the cell
culture is observable in the spectra recorded which allows the cells to be kept alive
for prolonged periods and spectroscopically monitored, effectively in real time.
After growing A549 and HaCaT (immortalised human keratinocyte) cells for
24 hours on collagen gels, the medium was substituted by NaCl before mapping,
as the phenol red of the cell growth medium limits the visibility of the cells [119].
Examples of photographs obtained using a Horiba Jobin - Yvon Labram HR800
equipped with a x100 immersion objective are presented in figure 13A and 13C.
The different structures of the cells can be identified; the cell membrane is clearly
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defined for both cell lines and the nucleus is located in the centre part of the cells.
The cytoplasm appears smaller in the case of the HaCaT cell. The main difference
between the two cell lines is the organisation in the nucleus. When observing the
A549 cells, the nucleoli are clearly visible inside the nucleus but in the case of the
HaCaT cell, no well defined shapes can be observed under these conditions. Another observation is the presence of 2 different organelles in the cytoplasm of the
A549 cell. This observation is not surprising as the cytoplasm of the cells has a
complex organisation and different structures can be found such as the actin or
microtubules [135, 136], endoplasmic reticulum[136, 137], the mitochondria [138]
or the Golgi apparatus[139, 140].

Figure 13: A and C are examples of images taken from the Labram HR 800
equipped with x100 immersion objective respectively from a A549 cell and a HaCaT cell. B and D are the corresponding false colors images obtained after Kmeans cluster analysis of Raman maps . Each pixel of the Raman map has been attributed to a specific cluster. The cluster numbers are indicated in the colour code
to the right of the figure. (Reproduced from [122])
Raman spectral maps were performed in immersion using a Horiba Jobin Yvon
LabRam HR800 using a 785nm laser as source. The step between two successive
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measurements was set to 1.5 µm and the backscattered Raman signal was integrated for 10 seconds over the spectral ranges from 400 to 1800 cm-1 and accumulated twice to improve the signal to noise ratio. In order to visualise the subcellular
structures in the spectral maps recorded, K-means clustering analysis was employed.

Figure 14: Average spectra obtained from different cluster after K- means clustering analysis. A: nucleus; B: nucleolus; C: cytoplasm cluster 1 and D: cytoplasm
cluster 2. (Reproduced from [122])
K-means clustering analysis is one of the simplest unsupervised learning algorithms used for spectral image analysis. It groups the spectra according to their
similarity, forming clusters, each one representing regions of the image with identical molecular properties [141]. The distribution of chemical similarity can then
be visualised across the sample image. The number of clusters (k) has to be determined a priori by the operator before initiation of the classification of the data
set. K centroids are defined, ideally as far as possible from each other, and then
each point belonging to a data set is associated to the nearest centroid. When all
the points have been associated with a centroid, the initial grouping is done. The
second step consists of the calculation of new centroids as barycentres of the clusters resulting from the previous step. A new grouping is implemented between the
same data points and the new centroids. These operations are repeated until convergence is reached and there is no further movement of the centroids. Finally k
clusters are determined, each containing the most similar spectra from the image.
From here, colours can be attributed to each cluster and false colour maps can be
constructed to visualise the organisation of the clusters in the original image.
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K-means clustering analysis is currently commonly used for the analysis of tissue sections by infrared and Raman spectroscopy, especially for the detection of
the different structures present in the samples studied and the identification of tumoral regions [142-144]. K-means clustering can also be employed for the study
of individual cells by Raman spectroscopy but only a few studies have elucidated
the subcellular organisation and they are usually based on fixed cells grown on a
non optimal substrate such a quartz window or equivalent [127, 145, 145]. The effects of cell fixation on the cellular composition has been already investigated
[129, 130] and thus it is desirable to be able to obtain the Raman signature from
live cells, avoiding any structural and molecular modification which may occur as
a result of the chemical processing. Moreover, the use of collagen gels enables extended measurement periods and thus more detailed mapping of live cells. In contrast to quartz substrates which have a toxic effect necessitating fixation of the
cells for prolonged measurement times, collagen gels offer a better adhesion of the
cells to the substrate, enhancing the cell viability.
Within the cells, it may be predicted that distinct biochemical regions can be
identified, corresponding to, for example, nucleus, nucleoli, cytoplasm and cell
membrane. However, in analysing the spectral response of the cells, it is observed
that the spectra recorded from the edge of the cells contain a high variability due
to the transition from the membrane to the substrate, resulting in quite noisy spectra. When the K-means analysis is performed, the variability between these spectra
can interfere with the analysis, resulting in the creation of new clusters. Thus, in
order to best visualise the different structures existing inside the cells the numbers,
the number of clusters has to be increased to 10 groups, which produced the best
reproducibility. In this way, the variability in the spectra obtained at the edge of
the cells are contained in different clusters and do not interfere with the identifications of the different structures present within the cells. The initiation step was selected randomly for each iteration and it was seen to have no effect on the final results of analysis. After analysis, the spectra were gathered in the 10 different
groups according to their similarities and a colour (arbitrarily) attributed to each
cluster. False colour maps were then constructed representing the partition of the
different clusters in the cells. The resulting images are presented in figure 13B and
13D. A correspondence between the organisation of the clusters and the structure
present in the cells can be seen. In figure 13B, specific clusters relating to the cytoplasm, nucleus and nucleoli appear. The specificity of the information contained
in the spectra recorded allows discrimination of the different cellular compartments using K-means analysis. The sensitivity of the analysis furthermore allows
visualization of the two different compartments present in the cytoplasm of the
A549 cell and identifies a specific cluster related to the nucleoli in the HaCaT cell,
although they are not clearly seen in the visible image.
K-means clustering analysis appears to be a powerful tool to identify the different structures present in the cells. The false colour maps give a representation of
the partition of the different clusters but do not provide any information about the
chemical composition of the samples. This biochemical information and the varia-
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tions between the different clusters can be visualised through the mean spectra of
the clusters. Figure 14 presents the average spectra obtained from selected clusters
of the K-means analysis performed on an A549 cell (Figure 13B). (A: nucleus
from the cluster number 4, B: nucleolus from the cluster number 6, C: cytoplasm
from the cluster number 5 and D: cytoplasm from the cluster number 7). The other
clusters correspond to the spectra recorded from the collagen gel and those located
at the edge between the cell and the substrate (data not shown). Variations can be
observed in different spectral windows according to the different clusters (highlighted in grey in figure 14).
The characterisation of live cells on 2D substrates is well documented [123,
124, 147-149] and, based on literature; assignments of the different peaks can be
performed. For example, the variations in the spectral range 718 -725 cm-1 are related to the lipids and nucleic acids, between 815 and 830 cm-1 to RNA and proteins, from 1088 cm-1 to 1102 cm-1 to the nucleic acids, the lipids and carbohydrates, from 1243-1266 cm-1 to the nucleic acids, the proteins and lipids, from
1296-1322 cm-1 to the lipids and from 1315-1348 cm-1 to the nucleic acids and
proteins. In analysing the cluster average spectra, it is important to note that, with
a ~1.5 m spot size, while the nucleus can be specifically targeted, the overlying
cellular membrane and cytoplasm will also contribute to the spectrum acquired.
Similarly, the spectrum of the cytoplasm will contain contributions from the overlying cellular membrane and potentially also from subcellular organelles such as
mitochondria, lysosomes, etc.. Across, the spectral range, the variations between
the different regions are thus subtle. However, the regions do clearly cluster by Kmeans analysis, and for example the nucleus and nucleoli are clearly differentiated
from the other spectra by for example the peak at 1423 cm-1, which is completely
absent in the cytoplasmic spectra.
The mean spectra obtained from each cluster provide information about the
spectral ranges which differentiate the sub-structures of the cells. However, it is
difficult to determine precisely the differentiating features and to profile the biochemical structure of the cellular compartment analysed. Using K-means clustering analysis, the different structures of the cells have been identified and spectra
associated with the nucleus, nucleoli and cytoplasm can now be extracted from the
map and analysed independently to highlight the modification in the spectral signatures. For this purpose, principal component analysis (PCA) was employed, for
the case of the A549 cells for illustration purposes [150]. Similar results are obtainable for the HaCaT cell line. Figure 15 is a representation of the plots obtained
from the spectra extracted from the A549 cell map. Each spectrum has been considered as a single unit for the analysis and the difference compared to K-means
analysis is that PCA is a totally unsupervised method. The result is a representation of the discrimination between the different spectra. Figure 15A is a plot of PC
1 versus PC 2 for each spectrum. The spectra from the nucleus and nucleoli form
one group and are not discriminated by these principal components. Nevertheless,
PC 1, which represents 34% of the explained variance, gives a good discrimination between the spectra from compartment 1 of the cytoplasm from the other
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spectra (this can also be seen in figure 15C) whereas PC 2, which represents 23%
of the variance, allows the discrimination between compartment 2 of the cytoplasm and the other spectra. The second plot (figure 15B) represents the loadings
of PC 2 versus PC 3. PC 2 again gives a clear discrimination between the spectra
from compartment 2 of the cytoplasm and the other spectra, as seen in figure 15A.
PC 3, which represents 3.5% of the explained variance, discriminates between the
spectra from the nucleus and those from the nucleoli. The same observation can be
made in figure 15C. PCA thus provides a clear discrimination between the different groups of spectra analysed. The results are not surprising, as the spectra have
been extracted from different clusters obtained after the K-means analysis and no
additional information about the chemical composition of the samples is given in
the plots. Nevertheless, the observation of the plots is essential to identify the
principal component involved in the discrimination between the different groups,
as for each principal component a corresponding loadings is given after analysis.

Figure 15: Plots of the ﬁrst 3 principal components after PCA performed on Raman spectra recorded from A549 cells grown on collagen gels. The spectra have
been selected for the cluster corresponding to the nucleus (red), nucleolus (green)
and cytoplasm (cluster 1: dark blue; cluster 2: light blue). (Reproduced from
[122])
The loading is a representation of the variability described by a principal component as a function of wavenumber of the spectra. Figure 16A shows the loading
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of PC1 obtained from the PCA analysis based on the A549 cell map which allows
visualisation of which part of the spectrum is responsible for the discrimination
between compartment 1 of the cytoplasm and the other spectra, observed in the
plot of figure 15. The loading is a combination of different peaks with different intensities, the solid red line representing the zero level. It appears that the loading is
composed of different sharp peaks, both positive and negative, and correspond to
increased or decreased contributions of specific molecular components to the Raman spectra. The spectra in figure 16 B,C,D and E, offset for clarity, are from
DNA, RNA, L-α-Phosphatidylcholine and Sphingomyelin respectively. DNA and
RNA are abundantly present, especially in the nucleus, phosphatidylcholine is a
major component of biological membranes and sphingomyelin is also found in animal cell membranes. To demonstrate further the origin of the spectral variations,
and their clustering using PCA, the 12 peaks with highest variability have been
highlighted in figure 16A. Each of them has a correspondence with one or more of
the four spectra from compounds tested. For example, the peak at 791 cm-1 is
prominent in the spectra of DNA and RNA. In figure 14, it can be seen that while
all average spectra exhibit a peak in this region, it is significantly stronger in the
spectra of the nucleus and nucleoli, thus giving rise to a strong positive contribution to PC1, which differentiates between nucleus/nucleoli and cytoplasm 1. The
strongest variation, however, is the negative peak at 1439 cm-1, which is prominent in the spectra of the L-α-Phosphatidylcholine and Sphingomyelin indicating
significant variations in lipidic content. The loading of PC2, plotted in figure 17A
is the basis of the discrimination between compartment number 2 of the cytoplasm
and the nucleus and nucleoli (figure 15A). Once again the comparison with the
spectra of pure compounds highlights peaks matching with the loading. The highest variability can be seen at 699 cm-1 and 1436 cm-1, both attributed to the lipid
content, and at 1342 cm-1, related to the DNA and RNA. The loading of PC3
(figure 18A) represents the variability between the nucleus and the nucleolus (figure 15B and 15C). Many peaks can be identified as related to the DNA and RNA,
especially at 651, 813, 1091, 1482 and 1572 cm-1, showing that the main difference between the spectroscopic signatures of the nucleus and nucleolus is the
DNA/RNA content.
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Figure 16: Plot of the loadings number 1 (A) corresponding to the first principal
component resulting of the PCA analysis. This loading has been compared with
spectra recorded from different compounds: DNA (B) RNA (C) L-αPhosphatidylcholine (D) and Sphingomyelin (E). (Reproduced from [122])

Figure 17: Plot of the loadings number 2 (A) corresponding to the second principal component resulting of the PCA analysis. This loading has been compared
with spectra recorded from different compounds: DNA (B), RNA (C), L-αPhosphatidylcholine (D) and Sphingomyelin (E). (Reproduced from [122])
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Figure 18: Plot of the loadings number 3 (A) corresponding to the third principal
component resulting of the PCA analysis. This loading has been compared with
spectra recorded from different compounds: DNA (B) RNA (C) L-αPhosphatidylcholine (D) and Sphingomyelin (E). (Reproduced from [122])
The loadings of the principal components provide a multivariate profile of the
biomolecular variations within the cell. While a detailed analysis is not undertaken
here, it is clear that a wealth of information can be derived from the Raman analysis of single cells. In contrast to other studies, the work presented here is conducted on live cells rather than chemically preserved, and moreover the details of the
spectra are greatly enhanced by the minimal need for data-preprocessing and prolonged measurement periods. These conditions are facilitated by the use of collagen 3-D matrices for cell growth and measurement.
NanoParticles in Cells [151]
The potential of vibrational, particularly Raman, spectroscopy as a realtime label free subcellular analytical technique opens up a range of applications, as for
example in the field of nanotoxicology and nanomedicine. One of the major concerns regarding the possible toxic effects of nanoparticles is the capacity of these
materials to penetrate cells and possibly translocate to other cells around the body.
Conventional in vitro cytotoxicity assays, such as Alamar Blue, Neutral Red,
MTT, etc, provide indications of impact on cell proliferation, viability, metabolic
activity, lysosomal and mitochondrial activity. However, they fail to provide a
verification of nanoparticle internalisation or elucidate intracellular trafficking
mechanisms and subcellular distribution within cells. Indeed, false positive results
have been demonstrated due to the extracellular interaction of the nanoparticles
with the cell culture medium in vitro, and with the cytotoxic assays themselves
[152, 152]. The underlying principles of internalisation and distribution of nano-
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particles within cells and any associated toxicity to humans are still relatively
poorly understood. However, there are numerous studies that have demonstrated
the ability of nanoparticles to cross membranes and internalise within many different cell types [153-155]. In order to assess potential risks, but also benefits in
terms of nanomedicine, a greater understanding of migration of nanoparticles intra- and inter-cellularly and essentially from one part of the body to another, along
with information on the translocation of nanoparticles within organelles, is urgently required.
Among the main challenges faced by nanotoxicologists are the detection and
identification of nanoparticles that have crossed the cell membrane and monitoring
of their intracellular trafficking. Imaging cells exposed to fluorescently labelled
nanoparticles using confocal fluorescence microscopy is one of the most common
ways in which to ensure nanoparticles can be tracked and monitored as they enter
and localise within cells [156-158]. However, not all nanoparticles can be easily
fluorescently labelled. Furthermore, there have been reports that labelled nanoparticles can release the dye into the surrounding biological environment, and so the
distribution of fluorescence within the cell does not necessarily represent the presence or subcellular distribution of the nanoparticles [159-161]. Furthermore, it is
not clear that the transport mechanisms of smaller nanoparticles, fluorescently labelled with anionic moieties, are the same as their unlabelled counterparts. Transmission Electron Microscopy can also be employed to visualise nanoparticles
within cells, but significant sample processing (fixing and ultramicrotoming) is
required and only particles with sufficient electronic contrast to the cellular environment can be visualized [162, 163]. Thus, there is a requirement for a sensitive
technique to localise and identify nanoparticles internalised in cells, ideally based
on their chemical composition, rather than fluorescence labels or electronic contrast. Identification of their local environment (e.g. endosomes, lysosomes, mitochondria) could aid in elucidating their intracellular trafficking and interaction
mechanisms, and the resulting changes in cellular metabolism.
Raman spectroscopy potentially offers a label free probe of nanoparticles within cells, which can potentially analyse their local environment, and ultimately
changes in the cellular metabolism which can be correlated with cytotoxic responses [164], oxidative stress, or inflammation. Kneipp et al. have previously
demonstrated the use of Surface Enhanced Raman Scattering from gold nanoparticles and nanoaggregates to probe the environment of the subcellular compartments
through which they are trafficked [165, 166]. They have also demonstrated the use
of molecular labelled nanoparticles as more specific probes of the local environment [167-169]. However, the uptake rates and mechanisms as well as the subsequent trafficking may be specific to the nanoparticle type, size and surface chemistry. Furthermore, the molecular specificity of the surface enhancement process is
not well understood. Therefore, a truly label free method for monitoring and characterising the cellular uptake and subcellular localisation of nanoparticles in general is still required.

35

It has been demonstrated that, based on the spectroscopic fingerprint of polystyrene, Raman spectroscopy, coupled with routine multivariate analyses such as
K-means clustering, is a more specific probe to detect and localise nanoparticles
within cells [151]. Furthermore, Principal Component Analysis can be employed
to differentiate the local environment of the nanoparticles from the cytoplasm. For
convenience, formalin fixed (A549) cells were employed. Raman mapping was
performed in immersion using a x100 Olympus LUMPlanF1 objective, a wavelength of 785nm, and a step size of 0.75m. As seen in figure 13, using a 100x objective, the visible image obtained from the cells is rather detailed (Figure 19 IA).
The nucleus is clearly identifiable and the nucleoli can also be seen. The membrane of the cells is well defined and the cytoplasm presents different structures
and the region containing the endoplasmic reticulum can be easily recognised. As
in the previous section, K-means cluster analysis of the Raman spectral map using
10 clusters clearly differentiates the sub-cellular regions of interest (Figure 19 IB).
(I)

(II)

(III)

Figure 19: I; (A) Microscopic image of an A549 cell, showing the reduced area
identified for spectral mapping. (B) K-means cluster map of the Raman profile of
the same reduced area. II; K-means spectra of clusters 3 (A – representing nucleoli), 6 (B – representing nucleus), 1 and 4 (C and D, both from the cytoplasm).
Spectra are offset for clarity. III; K-means spectrum of Cluster 5 (A), compared to
the Raman spectrum polystyrene nanoparticles (B). Spectra are offset for clarity.
(Reproduced from [151])
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The nucleoli spectra form a specific group (cluster 3), distinct from the nucleus
(cluster 6). The corresponding mean spectra are displayed in figure 19 II. The cytoplasm is represented by a number of different clusters (1, 2, 4, 8, 9, 10). Notably,
nanopolysterene can now be localised in the cytoplasm according to cluster 5, the
corresponding mean spectrum of which is presented in figure 19 IIIA. Although
some cellular features clearly contribute to the cluster spectrum, it is dominated by
specific features originating from polystyrene (figure 19 IIIB). K-means cluster
analysis yields the average spectra for the identified clusters. These average spectra can contain contributions from points on the boundaries between the cellular
regions and a direct comparison does not always easily facilitate identification of
the differences in the biochemical composition. Cluster 5 clearly identifies the
presence of polystyrene nanoparticles localised in the cytoplasm, but the averaged
spectrum also exhibits clear contributions of the biological environment. PCA can
be employed to highlight the biochemical differences between the subcellular regions [150]. In figure 19 IB, cluster 5 is predominantly surrounded by cytoplasmic
regions grouped within cluster 1. Figure 20 (top) is a scatter plot of the PCA of
spectra associated with K-means clusters 1 and 5. For visualisation purposes,
spectra associated with cluster 1 are coloured blue, while those from cluster 5 are
coloured green, and although the data is rather dispersed, some differentiation between the two clusters according to PC1 is apparent. PC1 accounts for 61% of the
variance and, as shown in the loadings plot of figure 20 (bottom), it is dominated
by positive contributions of polystyrene (figure 20 B). Notably, the negative contributions of PC1 match well with the Raman features of lipids such as L-αPhosphatidylcholine (figure 20 C) and also sphingomyelin (figure 20 D). For
comparison, the Raman spectra of DNA (figure 20 E) and RNA (figure 20 F) are
also shown, and it is clear that they exhibit few or no similarities with PC1. High
loadings of PC1 for cluster 5 are therefore an indication of the dominance of polystyrene. Positive loadings of PC1 for some of Cluster 1 may indicate regions of
overlap between the localised nanoparticles and the surrounding cytoplasm,
which, although they have significant polystyrene contributions, are represented in
the K-means cluster analysis by the average spectrum of cluster 1.
An established mechanism for the transport of nanoparticles in cells is via endosomes and later lysosomes [170]. A number of studies have also demonstrated
that, in the later stages of trafficking, individually endocytosed nanoparticles accumulate in larger multivescular bodies [165] and they have also been seen to be
localized in the endoplasmic reticulum and Gogli apparatus [171]. Notably, in figure 19 IA, the majority of the nanoparticles, identified in green as cluster 5, are
surrounded by cytoplasmic regions of cluster 1, which is relatively spatially extensive, particularly compared to typical sizes of lysosomes (1-2m). In the white
light image of figure 19 IB, this region can be identified as the Endoplasmic Reticulum (ER), which may be expected to be rich in lipidic compounds, and a PCA
of the different regions of the cytoplasm confirms this. Cluster 4, on the other
hand is relatively rich in nucleic acids, which may be due to the presence of mitochondria. Co-staining the cells to highlight the ER and examination using confocal
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fluorescence microscopy indicates a strong correlation between the ER stain and
the fluorescence of the nanoparticle label, and any locally concentrated fluorescence which may be indicative of encapsulated nanoparticles is contained within
the ER [151]. The analysis supports the attribution of the subcellular environment
of K-means cluster 1 as endoplasmic reticulum.

Figure 20: Top; Scatter plot of the PCA of spectra associated with clusters 1
(Blue) and 5 (Green). Bottom; (A) Loading of PC1 (B) Raman Spectrum of polystyrene nanoparticles (C) of L--Phosphatidylcholine, (D) of Sphingomyelin, (E)
of DNA and (F) of RNA. (Reproduced from [151])
The study represents an initial proof of concept, to demonstrate the potential
use of Raman spectroscopy to identify and locate nanoparticles in cells and to
probe their subcellular environment. No attempt has, as yet, been made to quantify
the amount of nanoparticles located or the sensitivity and detection limit of the
technique. Instrumentally, the spatial resolution can be improved by moving to
lower wavelength sources, although the excitation of any fluorescence from the
nanoparticles and the cell constituents should be avoided. However, as it scales
linearly with wavelength, a move from 785 nm to 473 nm should result in an improvement in lateral resolution by a factor of ~1.7. Ultimately, the confocal mode
of operation can provide 3D localisation of the nanoparticles at submicron resolution.
Other multivariate analytical approaches have also been applied in the field of
Raman microspectroscopy of cells. In addition to KMCA, other clustering methods such as Fuzzy C means clustering (FCM) and hierarchal cluster analysis
(HCA) have been used to separate the cellular Raman data into clusters and subsequently reshape the data into images [172, 173]. However, as highlighted by
Headegaad et al., these approaches have their own limitations. In particular,
boundaries between sub-cellular features can often result in the addition of extra
clusters with mixed spectral signatures. This can be overcome by increasing the
number of clusters; however, this in turn can result in added complexity to interpretation and inaccuracies in regional separation. Additionally, the reproducibility
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of these methods can also be questioned as the starting point for the centroid based
KMCA and FCM is subjective [172].
PCA and vertex component analysis (VCA) have also been used to separate out
distinct regions of the cell. With regards to PCA, separation is based on the variances between the spectra in the data set, the majority of the variance being described by the first three principal components [172]. Thus, the score values can
be used to construct a composite image of the cell in which the biochemical contributions of each component are described by the corresponding loadings plot.
Unlike KMCA and FCM, PCA identifies quite accurately the boundaries between
each feature. However, the images generated suffer from inferior contrast and in
some instances interpretation may be difficult as biochemical features may be
spread across different loadings.
VCA is another method which has been used for similar analytical purposes. In
brief, VCA computes a linear combination of supposed pure component spectra
which are termed endmember spectra. As described in Miljkovic et al., the
endmember spectra are acquired under the assumption that the most extreme data
points in the dataset are representative of pure component spectra [173]. However,
it has been pointed out that the endmembers generated are not truly representative
of the pure component they describe in the data set and can often contain a mixture of biochemical constituents i.e. DNA and proteins. While this is representative of the true nature of nucleic acids in-situ, it could lead to inaccuracies in interpretation.
A more recent study introduced the technique of spectral cross correlation to
screen spectral maps for the spatial distribution of specific spectral signatures, including those of polystyrene nanoparticles, RNA and lipids, and argued that it was
more effective than Classical least squared analysis, both supervised and unsupervised, which is commonly available on instrument software [174].
As in the case of multivariate techniques for disease diagnostics, there is a myriad of potential techniques to explore the spatial variations of the spectral profiles
with heterogeneous structures such as biological cells. A truly quantitative comparison of the different techniques is lacking, however.
Conclusions
Since their origins in the 19th and 20th centuries, the techniques of Infrared absorption and Raman scattering spectroscopy have come a long way. Technological
developments have rendered them routine benchtop techniques for chemical and
process analysis. Although their applications for the analysis of complex mixtures
have raised some challenges, an understanding of the fundamental physical processes and interactions has helped the scientific community address these challenges. In biomedical applications, the chemical and physical inhomogeneities of
cells and tissues have presented many such challenges, not easily understood by a
multidisciplinary community. However, concerted efforts through collaborative
programmes such as the EU FP6 Special Support Action DASIM [175] have
helped understand the origins of spectral artefacts which can mask or obscure the
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true information contained within a spectral profile, such that such effects can be
minimised by improved sample presentation and/or data preprocessing.
Over the past decades, the potential of vibrational spectroscopy for biomedical
applications has been extensively explored and demonstrated. The prospect is of a
truly label free, non-invasive, non destructive, rapid, automated and objective
technology for disease diagnostics and beyond. Disease diagnostics can be made
on the basis of true changes in biochemistry rather than for example cellular and
tissue morphology, and disease origin and progression can be better understood.
Gerwin Puppels, one of the pioneers of the field and founder of River Diagnostics
likens the developing technology to that of Dr. McCoy of Star Trek, whereby a
simple optical probe can scan a body for all ailments. While it may seem improbable, the emergence of spectroscopic probes for in vivo analyses and the development of applications for the analysis of bodily fluids and identification of spectral
markers of disease may mean the realisation of real clinical applications in the
near future.
Beyond disease diagnostics, EU legislation is placing increasing emphasis on in
vitro screening techniques for the replacement, reduction and refinement of animal
experimentation in scientific studies. High Content Analysis techniques for automation and higher throughput of screening based on chemical and immuno assays
have developed significantly over the past decade. However, the assays are highly
specific and the process of assaying is extremely expensive. In the realm of in
vitro diagnostics and therapeutics, vibrational spectroscopy presents as realistic alternative.
The development of applications of vibrational spectroscopy for biomedical/chemical applications has relied heavily on the development and application of
multivariate statistical and data mining techniques. A single spot on a cell or tissue
contains a multitude of different biochemical components in itself, and the composition and morphology of this complex melange can vary dramatically over a
length scale which is comparable to the sampled spot size. Cell to cell, tissue to
tissue, or patient to patient variability must also be considered. The challenge of
extracting relevant information is therefore immense, and a myriad of techniques
has been applied and adapted as exemplified in a multitude of techniques. Given
the impact of the conclusions derived, particularly in medical diagnostics, it is imperative that the combination of spectral analysis and data processing yield the
“right answer”. In a real life scenario, however, it is impossible to know for certain what the “right answer” is however. In this context, complex simulated data
sets which incorporate instrumental variabilities and measurement artefacts, but
also sample to sample variabilities may play a critical role in validating and optimising the data analytical techniques. With a combination of optimised spectroscopic technologies, sample presentation protocols and data processing and analysis techniques, the future for vibrational spectroscopy is bright, for disease
diagnostics and beyond.
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